Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Subjects With Advanced or Refractory Leukemia or Myelodysplastic Syndrome

NCT00676728 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.

NCT NCT00676728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00676728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Subjects With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2008
Completion date
September 30, 2011
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or refractory leukemia, myelodysplastic syndromes